Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells.

Mohr A, Chu T, Brooke GN, Zwacka RM.

Cancers (Basel). 2019 Apr 21;11(4). pii: E568. doi: 10.3390/cancers11040568.

2.

Efficacy and Safety of Human Retinal Progenitor Cells.

Semo M, Haamedi N, Stevanato L, Carter D, Brooke G, Young M, Coffey P, Sinden J, Patel S, Vugler A.

Transl Vis Sci Technol. 2016 Jul 19;5(4):6. eCollection 2016 Jul. Erratum in: Transl Vis Sci Technol. 2016 Dec 1;5(6):8.

3.

Advances in genetics: widening our understanding of prostate cancer.

Pine AC, Fioretti FF, Brooke GN, Bevan CL.

F1000Res. 2016 Jun 27;5. pii: F1000 Faculty Rev-1512. doi: 10.12688/f1000research.8019.1. eCollection 2016. Review.

4.

Multipotent human stromal cells isolated from cord blood, term placenta and adult bone marrow show distinct differences in gene expression pattern.

Matigian N, Brooke G, Zaibak F, Rossetti T, Kollar K, Pelekanos R, Heazlewood C, Mackay-Sim A, Wells CA, Atkinson K.

Genom Data. 2014 Nov 28;3:70-4. doi: 10.1016/j.gdata.2014.11.011. eCollection 2015 Mar.

5.

Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.

Brooke GN, Gamble SC, Hough MA, Begum S, Dart DA, Odontiadis M, Powell SM, Fioretti FM, Bryan RA, Waxman J, Wait R, Bevan CL.

Mol Cell Proteomics. 2015 May;14(5):1201-16. doi: 10.1074/mcp.M113.036764. Epub 2015 Feb 18.

6.

Triphenylarsonium-functionalised gold nanoparticles: potential nanocarriers for intracellular therapeutics.

Lalwani N, Chen YS, Brooke G, Cross NA, Allen DW, Reynolds A, Ojeda J, Tizzard GJ, Coles SJ, Bricklebank N.

Chem Commun (Camb). 2015 Mar 7;51(19):4109-11. doi: 10.1039/c4cc09304f.

PMID:
25670649
7.

The co-chaperone p23 promotes prostate cancer motility and metastasis.

Cano LQ, Lavery DN, Sin S, Spanjaard E, Brooke GN, Tilman JD, Abroaf A, Gaughan L, Robson CN, Heer R, Mauri F, de Rooij J, Driouch K, Bevan CL.

Mol Oncol. 2015 Jan;9(1):295-308. doi: 10.1016/j.molonc.2014.08.014. Epub 2014 Sep 6.

8.

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer.

Rudraraju B, Droog M, Abdel-Fatah TM, Zwart W, Giannoudis A, Malki MI, Moore D, Patel H, Shaw J, Ellis IO, Chan S, Brooke GN, Nevedomskaya E, Lo Nigro C, Carroll J, Coombes RC, Bevan C, Ali S, Palmieri C.

Breast Cancer Res Treat. 2014 Sep;147(2):295-309. doi: 10.1007/s10549-014-3098-0. Epub 2014 Aug 22.

PMID:
25141981
9.

Revising the role of the androgen receptor in breast cancer.

Fioretti FM, Sita-Lumsden A, Bevan CL, Brooke GN.

J Mol Endocrinol. 2014 Jun;52(3):R257-65. doi: 10.1530/JME-14-0030. Epub 2014 Apr 16. Review.

PMID:
24740738
10.

Engineered repressors are potent inhibitors of androgen receptor activity.

Brooke GN, Powell SM, Lavery DN, Waxman J, Buluwela L, Ali S, Bevan CL.

Oncotarget. 2014 Feb 28;5(4):959-69.

11.

Circulating nucleic acids as biomarkers of prostate cancer.

Sita-Lumsden A, Fletcher CE, Dart DA, Brooke GN, Waxman J, Bevan CL.

Biomark Med. 2013 Dec;7(6):867-77. doi: 10.2217/bmm.13.104. Review.

12.

Characterisation of the androgen regulation of glycine N-methyltransferase in prostate cancer cells.

Ottaviani S, Brooke GN, O'Hanlon-Brown C, Waxman J, Ali S, Buluwela L.

J Mol Endocrinol. 2013 Nov 7;51(3):301-12. doi: 10.1530/JME-13-0169. Print 2013 Dec.

13.

Engraftment Outcomes after HPC Co-Culture with Mesenchymal Stromal Cells and Osteoblasts.

Cook MM, Doran MR, Kollar K, Barbier V, Winkler IG, Levesque JP, Brooke G, Atkinson K.

J Clin Med. 2013 Sep 23;2(3):115-35. doi: 10.3390/jcm2030115.

14.

Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer.

Reebye V, Querol Cano L, Lavery DN, Brooke GN, Powell SM, Chotai D, Walker MM, Whitaker HC, Wait R, Hurst HC, Bevan CL.

Mol Endocrinol. 2012 Oct;26(10):1694-706. Epub 2012 Aug 16.

15.

Allosteric conversation in the androgen receptor ligand-binding domain surfaces.

Grosdidier S, Carbó LR, Buzón V, Brooke G, Nguyen P, Baxter JD, Bevan C, Webb P, Estébanez-Perpiñá E, Fernández-Recio J.

Mol Endocrinol. 2012 Jul;26(7):1078-90. doi: 10.1210/me.2011-1281. Epub 2012 May 31.

16.

Closed system isolation and scalable expansion of human placental mesenchymal stem cells.

Timmins NE, Kiel M, Günther M, Heazlewood C, Doran MR, Brooke G, Atkinson K.

Biotechnol Bioeng. 2012 Jul;109(7):1817-26. doi: 10.1002/bit.24425. Epub 2012 Jan 17.

PMID:
22249999
17.

Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens.

Dart DA, Brooke GN, Sita-Lumsden A, Waxman J, Bevan CL.

Oncogene. 2012 Oct 25;31(43):4588-98. doi: 10.1038/onc.2011.591. Epub 2011 Dec 19.

18.

Comprehensive transcriptome and immunophenotype analysis of renal and cardiac MSC-like populations supports strong congruence with bone marrow MSC despite maintenance of distinct identities.

Pelekanos RA, Li J, Gongora M, Chandrakanthan V, Scown J, Suhaimi N, Brooke G, Christensen ME, Doan T, Rice AM, Osborne GW, Grimmond SM, Harvey RP, Atkinson K, Little MH.

Stem Cell Res. 2012 Jan;8(1):58-73. doi: 10.1016/j.scr.2011.08.003. Epub 2011 Aug 17. Erratum in: Stem Cell Res. 2012 Jul;9(1):58.

19.

Micromarrows--three-dimensional coculture of hematopoietic stem cells and mesenchymal stromal cells.

Cook MM, Futrega K, Osiecki M, Kabiri M, Kul B, Rice A, Atkinson K, Brooke G, Doran M.

Tissue Eng Part C Methods. 2012 May;18(5):319-28. doi: 10.1089/ten.TEC.2011.0159. Epub 2012 Jan 4.

PMID:
22082070
20.

Development of myocardial constructs using modulus-matched acrylated polypropylene glycol triol substrate and different nonmyocyte cell populations.

Hudson JE, Brooke G, Blair C, Wolvetang E, Cooper-White JJ.

Tissue Eng Part A. 2011 Sep;17(17-18):2279-89. doi: 10.1089/ten.TEA.2010.0743. Epub 2011 Jun 28.

PMID:
21542698
21.

Manufacture of clinical grade human placenta-derived multipotent mesenchymal stromal cells.

Ilic N, Brooke G, Murray P, Barlow S, Rossetti T, Pelekanos R, Hancock S, Atkinson K.

Methods Mol Biol. 2011;698:89-106. doi: 10.1007/978-1-60761-999-4_8.

PMID:
21431513
22.

FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth.

Brooke GN, Culley RL, Dart DA, Mann DJ, Gaughan L, McCracken SR, Robson CN, Spencer-Dene B, Gamble SC, Powell SM, Wait R, Waxman J, Walker MM, Bevan CL.

Cancer Res. 2011 Feb 1;71(3):914-24. doi: 10.1158/0008-5472.CAN-10-0874. Epub 2010 Dec 17.

23.

Age as a risk factor for perioperative complications in women undergoing pelvic reconstructive surgery.

Moore T, Tubman I, Levy G, Brooke G.

Female Pelvic Med Reconstr Surg. 2010 Sep;16(5):290-5. doi: 10.1097/SPV.0b013e3181e128b6.

PMID:
22453507
24.

A synthetic elastomer based on acrylated polypropylene glycol triol with tunable modulus for tissue engineering applications.

Hudson JE, Frith JE, Donose BC, Rondeau E, Mills RJ, Wolvetang EJ, Brooke GP, Cooper-White JJ.

Biomaterials. 2010 Nov;31(31):7937-47. doi: 10.1016/j.biomaterials.2010.07.007. Epub 2010 Aug 4.

PMID:
20688386
25.

A defined medium and substrate for expansion of human mesenchymal stromal cell progenitors that enriches for osteo- and chondrogenic precursors.

Hudson JE, Mills RJ, Frith JE, Brooke G, Jaramillo-Ferrada P, Wolvetang EJ, Cooper-White JJ.

Stem Cells Dev. 2011 Jan;20(1):77-87. doi: 10.1089/scd.2009.0497. Epub 2010 Nov 9.

PMID:
20446813
26.

Molecular mechanisms involved in mesenchymal stem cell migration to the site of acute myocardial infarction.

Kollar K, Cook MM, Atkinson K, Brooke G.

Int J Cell Biol. 2009;2009:904682. doi: 10.1155/2009/904682. Epub 2009 Jul 12.

27.

Cellular therapy for repair of cardiac damage after acute myocardial infarction.

Cook MM, Kollar K, Brooke GP, Atkinson K.

Int J Cell Biol. 2009;2009:906507. doi: 10.1155/2009/906507. Epub 2009 Mar 29.

28.

Enhanced chondrogenic differentiation of human bone marrow-derived mesenchymal stem cells in low oxygen environment micropellet cultures.

Markway BD, Tan GK, Brooke G, Hudson JE, Cooper-White JJ, Doran MR.

Cell Transplant. 2010;19(1):29-42. doi: 10.3727/096368909X478560. Epub 2009 Oct 29.

PMID:
19878627
29.

The role of androgen receptor mutations in prostate cancer progression.

Brooke GN, Bevan CL.

Curr Genomics. 2009 Mar;10(1):18-25. doi: 10.2174/138920209787581307.

30.

Membrane bioreactors enhance microenvironmental conditioning and tissue development.

Doran MR, Markway BD, Clark A, Athanasas-Platsis S, Brooke G, Atkinson K, Nielsen LK, Cooper-White JJ.

Tissue Eng Part C Methods. 2010 Jun;16(3):407-15. doi: 10.1089/ten.TEC.2009.0367.

PMID:
19622005
31.

Plasmodium knowlesi from archival blood films: further evidence that human infections are widely distributed and not newly emergent in Malaysian Borneo.

Lee KS, Cox-Singh J, Brooke G, Matusop A, Singh B.

Int J Parasitol. 2009 Aug;39(10):1125-8. doi: 10.1016/j.ijpara.2009.03.003. Epub 2009 Apr 7.

32.

Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials.

Brooke G, Rossetti T, Pelekanos R, Ilic N, Murray P, Hancock S, Antonenas V, Huang G, Gottlieb D, Bradstock K, Atkinson K.

Br J Haematol. 2009 Feb;144(4):571-9. doi: 10.1111/j.1365-2141.2008.07492.x. Epub 2008 Dec 5.

PMID:
19077161
33.

Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells.

Barlow S, Brooke G, Chatterjee K, Price G, Pelekanos R, Rossetti T, Doody M, Venter D, Pain S, Gilshenan K, Atkinson K.

Stem Cells Dev. 2008 Dec;17(6):1095-107. doi: 10.1089/scd.2007.0154.

PMID:
19006451
34.

Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta.

Brooke G, Tong H, Levesque JP, Atkinson K.

Stem Cells Dev. 2008 Oct;17(5):929-40. doi: 10.1089/scd.2007.0156.

PMID:
18564033
35.

Spatial field shifts in ocean acoustic environmental sensitivity analysis.

Dosso SE, Morley MG, Giles PM, Brooke GH, McCammon DF, Pecknold S, Hines PC.

J Acoust Soc Am. 2007 Nov;122(5):2560-70. doi: 10.1121/1.2783123.

PMID:
18189547
36.

Points to Consider in Designing Mesenchymal Stem Cell-Based Clinical Trials.

Brooke G, Rossetti T, Ilic N, Murray P, Hancock S, Pelekanos R, Atkinson K.

Transfus Med Hemother. 2008;35(4):279-285. Epub 2008 Jul 21.

37.
38.

Therapeutic applications of mesenchymal stromal cells.

Brooke G, Cook M, Blair C, Han R, Heazlewood C, Jones B, Kambouris M, Kollar K, McTaggart S, Pelekanos R, Rice A, Rossetti T, Atkinson K.

Semin Cell Dev Biol. 2007 Dec;18(6):846-58. Epub 2007 Sep 18. Review.

PMID:
18024097
39.

Immunosuppression by placental indoleamine 2,3-dioxygenase: a role for mesenchymal stem cells.

Jones BJ, Brooke G, Atkinson K, McTaggart SJ.

Placenta. 2007 Nov-Dec;28(11-12):1174-81. Epub 2007 Aug 22.

PMID:
17714779
40.

Clonal isolation and characterization of bone marrow stromal cells from patients with osteoarthritis.

Mareddy S, Crawford R, Brooke G, Xiao Y.

Tissue Eng. 2007 Apr;13(4):819-29.

PMID:
17371154
41.

Mechanisms of androgen receptor repression in prostate cancer.

Powell SM, Brooke GN, Whitaker HC, Reebye V, Gamble SC, Chotai D, Dart DA, Belandia B, Bevan CL.

Biochem Soc Trans. 2006 Dec;34(Pt 6):1124-7.

42.

Prohibitin, a protein downregulated by androgens, represses androgen receptor activity.

Gamble SC, Chotai D, Odontiadis M, Dart DA, Brooke GN, Powell SM, Reebye V, Varela-Carver A, Kawano Y, Waxman J, Bevan CL.

Oncogene. 2007 Mar 15;26(12):1757-68. Epub 2006 Sep 11.

PMID:
16964284
43.

Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family.

Brooke G, Holbrook JD, Brown MH, Barclay AN.

J Immunol. 2004 Aug 15;173(4):2562-70.

44.

Cutting edge: TREM-like transcript-1, a platelet immunoreceptor tyrosine-based inhibition motif encoding costimulatory immunoreceptor that enhances, rather than inhibits, calcium signaling via SHP-2.

Barrow AD, Astoul E, Floto A, Brooke G, Relou IA, Jennings NS, Smith KG, Ouwehand W, Farndale RW, Alexander DR, Trowsdale J.

J Immunol. 2004 May 15;172(10):5838-42.

45.

Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo.

Vigushin DM, Mirsaidi N, Brooke G, Sun C, Pace P, Inman L, Moody CJ, Coombes RC.

Med Oncol. 2004;21(1):21-30.

PMID:
15034210
46.

DEC-205 expression on migrating dendritic cells in afferent lymph.

Gliddon DR, Hope JC, Brooke GP, Howard CJ.

Immunology. 2004 Mar;111(3):262-72.

47.

Pyrazino[1,2-a]indole-1,4-diones, simple analogues of gliotoxin, as selective inhibitors of geranylgeranyltransferase I.

Vigushin DM, Brooke G, Willows D, Coombes RC, Moody CJ.

Bioorg Med Chem Lett. 2003 Nov 3;13(21):3661-3.

PMID:
14552752
48.

Characterization of the CD200 receptor family in mice and humans and their interactions with CD200.

Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M, Song Y, Jenmalm M, Gorman D, McClanahan T, Liu MR, Brown MH, Sedgwick JD, Phillips JH, Barclay AN.

J Immunol. 2003 Sep 15;171(6):3034-46.

49.

A novel MyD-1 (SIRP-1alpha) signaling pathway that inhibits LPS-induced TNFalpha production by monocytes.

Smith RE, Patel V, Seatter SD, Deehan MR, Brown MH, Brooke GP, Goodridge HS, Howard CJ, Rigley KP, Harnett W, Harnett MM.

Blood. 2003 Oct 1;102(7):2532-40. Epub 2003 Jun 12.

PMID:
12805067
50.

Crystal-amorphous polymer interface studied by neutron and x-ray scattering on labeled binary ultralong alkanes.

Zeng XB, Ungar G, Spells SJ, Brooke GM, Farren C, Harden A.

Phys Rev Lett. 2003 Apr 18;90(15):155508. Epub 2003 Apr 18.

PMID:
12732051

Supplemental Content

Loading ...
Support Center